A shadow economy for unlicensed slimming drugs is being driven by social media fitness personalities and vendors on messaging platforms, according to recent findings.
Experimental Drug Gaining Traction Via Social Media
Retatrutide, which remains in clinical trials, is being promoted by social media influencers for its supposed weight-reducing effects. Viewers are encouraged to message these accounts directly for source information, while also obtaining discount codes.
Active Trade on Social Networks
Additionally, a robust market exists on messaging services, where groups with thousands of members share comparison photos, injection guides and assertions of rapid UK delivery. Sellers market the drug there before redirecting customers to WhatsApp for transactions.
Understanding The Experimental Drug
This medication is an experimental injectable created by American pharmaceutical company Eli Lilly. The drug affects three intestinal hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Preliminary studies suggest it could assist individuals reduce up to 25% of their total weight. Nicknamed the “triple G”, the drug is being hailed digitally as the next Ozempic.
Healthcare Professionals Express Worries
Nevertheless, physicians and pharmacists have warned that the distribution of what remains an unlicensed drug in the UK is a cause for concern and could result in users administering products of uncertain source.
Some experts said the popularity for retatrutide could be linked to the rising price of approved slimming products such as Mounjaro.
Regulatory Status and Implementation
Marketing retatrutide on social media or messaging apps is illegal in the UK, as it is an unapproved drug that must not be promoted or distributed for personal consumption under the Human Medicines Regulations 2012.
Several influencers try to circumvent the regulations by referring to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled drug, but promotion and supply can still breach pharmaceutical, marketing, and consumer laws, risking fines, prosecution or prison.
Service Response and Content Removal
Based on the social media company, the service has removed problematic content and banned related hashtags and search suggestions. The company stated it was dedicated to maintaining the service secure and investing in strengthening compliance measures.
Online Trading Operations
Research also found groups with up to nine thousand participants selling retatrutide using the platform's integrated discovery tool, which functions like a public directory. Entering “retatrutide” immediately brings up groups with thousands of users, populated with images of weight loss, glowing reviews and step-by-step instructions for preparing or administering at home.
After minutes of entering one group, a vendor posted WhatsApp details, where most transactions take place. The seller sent an instruction manual and guaranteed shipping within two days. When asked whether the substance was authentic, one seller said: “You can’t be sure.” Another provided a photo of a supposed testing documentation. None asked about weight, health issues or past usage.
Item Information and Costs
Inside these groups, messages show dark colored packages with postal service labels, stating to include new batches. One message read: “It took eight of us to load them this morning.”
Customers can choose between dry substance containers, mixed at residence with sterile water, or pre-filled injectors typically priced at 160 pounds for 20mg. When asked how long a pen should last, vendors give conflicting responses ranging from a several days to “depends on your body”.
Platform Oversight and Security Actions
A representative for Telegram said it actively monitored dangerous material on its service including content that encouraged the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.
Healthcare Expert Warnings
“People are injecting substances they cannot confirm. Even if the research behind this drug is valid, these online versions may not include what they advertise,” said a pharmacy expert, the director of pharmacy at a pharmacy service.
A medical professional of an online medical service linked the surge in interest to recent cost increases for approved slimming drugs such as Mounjaro. “With costs increasing, individuals are using social media. But counterfeit injections are extremely risky. You cannot know what’s contained or whether the environment they were produced in was clean,” she explained.
Her team has already encountered patients harmed by personal administration from unconfirmed suppliers. “We recognize the frustration, but buying from Telegram or communication platforms is taking chances with your health,” stated the doctor. “These materials could be contaminated or improperly measured.”
Manufacturer Position
A representative from the pharmaceutical company stated retatrutide was in third stage clinical trials and had not been reviewed or authorized by any government authority globally. “Consequently at this point no one can market [it] for human use,” they said, adding that any product “falsely representing itself as a company investigational product not yet authorized … may subject users to possibly significant medical dangers”.
